By Brian Gormley
Wall Street Journal

U.S. pharmaceutical companies have long lived with generic rivals, and soon biotechnology concerns will face similar competition. Through the health-care reform law passed last year, Congress created a regulatory path for companies to introduce “biosimilars,” or nearly exact copies of biological drugs that have come off patent. Read More